Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2025-12-25 @ 9:43 PM
Study NCT ID:
NCT04519151
Status:
RECRUITING
Last Update Posted:
2023-06-08
First Post:
2020-08-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sponsor:
Sheba Medical Center
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
7405-20
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None